Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
暂无分享,去创建一个
J. Ahn | Yeon-Hee Park | W. Park | T. Ahn | Y. Im | Kyunghee Park | I. Do | Hae Hyun Jung | Ji-yeon Kim | Yoon-La Choi | Hyun-Tae Shin | Aeri Lee
[1] A. Jemal,et al. Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[2] P. Madureira,et al. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. , 2015, Pharmacogenomics.
[3] Taesung Park,et al. Personalized identification of altered pathways in cancer using accumulated normal tissue data , 2014, Bioinform..
[4] N. Navin,et al. Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.
[5] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[6] E. Perez,et al. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 , 2013, Cancer.
[7] E. Perez,et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[9] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[10] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[11] A. Wilm,et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets , 2012, Nucleic acids research.
[12] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[13] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[14] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[15] H. Hakonarson,et al. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data , 2011, Nucleic acids research.
[16] E. Petricoin,et al. Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors , 2011, Molecular Cancer Therapeutics.
[17] E. Perez,et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[19] S. Chandarlapaty,et al. Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor , 2010, Clinical Cancer Research.
[20] K. Gelmon,et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[22] Jenny G. Parvani,et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance , 2009, Molecular Cancer Therapeutics.
[23] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[24] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[25] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[26] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[27] Carlos L Arteaga,et al. Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.
[28] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[29] P. Hegde,et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles , 2007, Molecular Cancer Therapeutics.
[30] J. Baselga,et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. , 2007, Journal of the National Cancer Institute.
[31] Antonio Marchetti,et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features , 2006, International journal of cancer.
[32] J. Baselga,et al. Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation , 2006, The EMBO journal.
[33] L. Layfield,et al. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. , 2006, Human pathology.
[34] M. Campiglio,et al. Role of exon-16-deleted HER2 in breast carcinomas. , 2006, Endocrine-related cancer.
[35] W. Park,et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.
[36] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[38] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[39] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[40] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[41] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[42] M. Hung,et al. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells , 2000, Oncogene.
[43] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[44] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[45] S. Rombauts,et al. Analysis of RNA-Seq data with TopHat and Cufflinks for genome-wide expression analysis of jasmonate-treated plants and plant cultures. , 2013, Methods in molecular biology.
[46] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[47] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[48] A. Chaudhuri,et al. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .
[49] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.